DOCSLIB.ORG

Expression of Human Milk Proteins in Transgenic Plants

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Expression of Human Milk Proteins in Transgenic Plants (19) TZZ _ _T (11) EP 2 617 294 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: A23L 1/09 (2006.01) A23L 1/10 (2006.01) 24.07.2013 Bulletin 2013/30 A23L 1/105 (2006.01) A23L 1/185 (2006.01) A01H 5/10 (2006.01) C12N 15/82 (2006.01) (2006.01) (2006.01) (21) Application number: 12197243.4 C07K 14/485 C07K 14/65 C07K 14/79 (2006.01) A23L 1/30 (2006.01) A23L 1/305 (2006.01) C07K 14/81 (2006.01) (2006.01) (2006.01) (22) Date of filing: 14.02.2002 C12N 9/08 C12N 9/36 (84) Designated Contracting States: • Rodriguez, Raymond, L. AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU Davis, CA 95616 (US) MC NL PT SE TR • Hagie, Frank, E. Designated Extension States: Sacramento, CA 95834 (US) AL LT LV MK RO SI (74) Representative: Vossius & Partner (30) Priority: 14.02.2001 US 269199 P Siebertstrasse 4 02.05.2001 US 847232 81675 München (DE) (62) Document number(s) of the earlier application(s) in Remarks: accordance with Art. 76 EPC: •This application was filed on 14-12-2012 as a 02719020.6 / 1 367 908 divisional application to the application mentioned under INID code 62. (71) Applicant: Ventria Bioscience •Claims filed after the date of receipt of the divisional Sacramento, CA 95834-1219 (US) application (Rule 68(4) EPC.). (72) Inventors: • Huang, Ning Davis, CA 95616 (US) (54) Expression of human milk proteins in transgenic plants (57) The invention is directed to food and food addi- directed to improved infant formula comprising such food tive compositions comprising one or more human milk supplement composition. proteins produced in the seeds of a trangenic plant and methods of making the same. The invention is further EP 2 617 294 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 617 294 A1 Description Field of the Invention 5 [0001] The present invention relates to human milk proteins produced in the seeds of transgenic plants, seed extracts containing the proteins, transgenic plants and seeds, and methods for producing and using the same. References 10 [0002] The following references are cited herein, and to the extent they may be pertinent to the practice of the invention, are incorporated herein by reference. [0003] Alber and Kawasaki, Mol. and App/. Genet. 1:419-434, 1982. [0004] Aniansson, G. et al. (1990). "Anti- Adhesive Activity Of Human Casein Against Streptococcus Pneumoniae And Haemophilus lnfluenzae," Microb Pathog, 8(5):315-323. 15 [0005] Arnold R.R. et al., Infect Immun. 28:893-898, 1980. [0006] Ausubel F. M. et al., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, N.Y., 1993. [0007] Bhan, M.K. et al., J Pediatr Gastroenterol Nutr 7:208-213, 1988. [0008] Beatty, K., et al., "Kinetics of association of serine proteinases with native and oxidized alpha-1-proteinase 20 inhibitor and alpha-1-antichymotrypsin," J. Biol. Chem. 255:3931-3934, 1980. [0009] Boesman-Finkelstein M. and Finkelstein R.A. FEBS Letters, 144: 1-5, 1982. [0010] Bradford M. Analytical Biochem. 72:248-254, 1976. [0011] Brandt, et a/., Carlsberg Res. Commun. 50:333-345, 1985. [0012] Briggs, D, et al. (1981). Malting And Brewing Science - Volume 1, Malt And Sweet Wort (Chapman & Hall, New 25 York, 2nd edition). [0013] Briggs, D (1998). Malts And Malting (Blackie Academic And Professional, New York). [0014] Bullen J.J. et al., Br. Med, J. 1, 69-75, 1972. [0015] Carrell, R.W. et al. "Structure and variation of human alpha- 1-antitrypsin", Nature 298:329-334, 1983. [0016] Casta~no´n M.J. et al.,. Gene, 66:223-234, 1988. 30 [0017] Chandan R.C., J Dairy Sci, 51:606-607, 1968. [0018] Chong, D.K. and Langridge, W.H., Transgenic Res 9:71-8, 2000. [0019] Chowanadisai, W. and Lönnerdal, B., "Alpha- 1-antltrypsin and antichymotrypsin in human milk: origin, concen- trations, and stability", Am. J. Clin. Nutr. 2001 (in press). [0020] Chrispeels K., Ann. Rev. Plant Phys. Plant Mol. Biol. 42: 21-53, 1991. 35 [0021] Clark et a/., J. Biol. Chem. 264:17544-17550,1989. [0022] Davidson LA, et al. (1987). "Persistence Of Human Milk Proteins In The Breast- Fed Infant", Act Pediatric Scand 76(5):733-740. [0023] Davidson, L.A., and Lönnerdal, B. "Fecal alpha-1-antitrypsin in breast-fed infants is derived from human milk and is not indicative of enteric protein loss", Acta Paediatr. Scand. 79: 137-’141, 1990. 40 [0024] della-Cioppa et al., Plant Physiol. 84:965-968, 1987. [0025] Dellaporta S.L. et al., Plant Mol. Biol. Rep.1: 19-21, 1983. [0026] Depicker et al., Mol. Appl. Genet 1:561-573,1982. [0027] Dewey K.G. et al., J Pediatrics 126:696-702, 1995. [0028] Dewey K.G. et al., Pediatrics 89:1035-1041, 1992. 45 [0029] Dewey K.G. et al., Am J Clin Nutr 57: 140-145, 1993. [0030] Ditta et a/., Proc. Nat. Acad. Sci., U.S.A. 77:7347-7351, 1980. [0031] Doncheck, J (1995). Malts And Malting. In: Kirk- Othmer Encyclopedia Of Chemical Technology (John Wiley & Sons, New York, 4th edition), volume 15, pp. 947-962. [0032] Eley, E, (1990), A Wandful World. Food Processing August 1990, pp. 17-18 50 [0033] Faure A. and Jollès P., et al., Comptes Rendus Hebdomadaires des Seances de L Academie des Sciences. D: Sciences Naturelles, 271:1916-1918, 1970. [0034] Fujihara T. and Hayashi K., Archives of Virology 140:1469-1472, 1995. Gastañaduy, A. et al., J Pediatr Gas- troenterol Nutr 11:240-6, 1990. [0035] Gelvin, S.B. et al., eds. PLANT MOLECULAR BIOLOGY MANUAL, 1990. 55 [0036] Gielen, et al., EMBO J. 3:835-846, 1984. [0037] Goto, F et al., Nature Biotech. 17:282-286, 1999. [0038] Grover M. et al., Acta Paediatrica 86:315-316, 1997. [0039] Hamosh, M, et al. (1999). "Protective Function Of Human Milk: The Fat Globule,"_ Semin Perinatol 23 (3):242-9. 2 EP 2 617 294 A1 [0040] Harmsen M.C. et al, Journal of Infectious Diseases 172: 380-388, 1995. [0041] Hickenbotttom, JW (1977). Sweeteners in Biscuits And Crackers. The Bakers Digest, December 1977, pp. 18-22. [0042] Hickenbottom, JW (1983). AIB Research Department Technical Bulletin, V (3), March 1983, pp. 1-8. 5 [0043] Hickenbottom, JW (1996). Processing, Types, And Uses Of Barley Malt Extracts And Syrups, Cereal Foods World 41(10): 778-790. [0044] Hickenbottom JW (1997). Malts in Baking. American Society Of Bakery Engineers, Technical Bulletin #238, August 1997, pp. 1010-1013. [0045] Huang N. et al., Plant Mol. Biol., 23:737·747, 1993. 10 [0046] Hough, JS, et al. (1982).). Malting And Brewing Science - Volume 2, Hopped Wort And Beer (Chapman & Hall, New York, 2nd edition). [0047] Huang N. et al.; J CAASS, 1:73-86, 1990a. [0048] Horvath H. et al., Proc. Natl. Acad. Sci. USA, 97: 1914-1919, 2000. [0049] Humphreys, D.P. and Glover, D.J. "Therapeutic antibody production technologies: molecules, applications, 15 expression and purifcation," Curr Opin Drug Discov Devel Mar; 4(2): 172-85,2001. [0050] Huang N. et al., Plant Mol. Biol. 14:655-668, 1990b. [0051] Huang, J., et al., "Expression and purification of functional human alpha- 1-antitrypsin from cultured plant cells", Biotechnol. Prog. 17:126-133, 2001. [0052] Jensen L.G. et a/., Proc. Natl. Acad. Sci. USA, 93: 3487-3491, 1996. Jigami Y. et al., Gene, 43:273-279, 1986. 20 [0053] Johnson, T. "Human alpha-1-proteinase inhibitor", Methods Enzymol. 80:756-757,1981. [0054] Jollès P., LYSOZYMES-MODEL ENZYMES IN BIOCHEMISTRY AND BIOLOGY. Birkhäuser Verlag, Basel; Boston, 1996. [0055] Jouanin et al., Mol. Gen. Genet. 201:370-374, 1985. [0056] Kortt A.A. et al., "Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting," Biomol Eng 18: 25 95-108, 2001. [0057] Kovar M.G. et al., Pediatrics 74:615-638, 1984. [0058] Kunz C. et al., Clin. Perinatol. 26(2):307-33, 1999. [0059] Lake, C, (1988). From Strength To Strength. Flood Flavorings, Ingredients, Packaging And Processing, Feb- ruary 1988, pp. 55 -57. 30 [0060] Langridge et al., Planta 156:166-170, 1982. [0061] Larrick, J.W. et al., "Production of antibodies in transgenic plants", Res Immunol 149: 603-8, 1998. [0062] Lásztity, R. The chemistry of cereal proteins. CRC Press, Boca Raton, 1996. [0063] Lee-Huang S. et al., Proc. Natl. Acad. Sci. USA, 96: 2678-2681, 1999. [0064] Lindberg, T. "Protease inhibitors in human milk", Pediatr. Res. 13: 969-972, 1979. 35 [0065] Lollike K. et al., Leukemia, 9:206-209, 1995a. [0066] Lönnerdal B., Am L Clin Nutr, 42:1299-1317, 1985. [0067] Lönnerdal, B. "Recombinant milk proteins- an opportunity and a challenge", Am. J. Clin. Nutr. 63: 622S-626S, 1996. [0068] Maga E. et al., J. of Food Protection, 61: 52-56, 1998. 40 [0069] Maga E. et al., Transgenic Research, 3:36-42, 1994. [0070] Maga E. et al., Journal of Dairy Science, 78:2645-2652, 1995. [0071] Maniatis, et al, MOLECULAR CLONING: A LABORATORY MANUAL, 2nd Edition, 1989. [0072] Matsumoto, A. et al., Plant Mol Bio 27:1163-72, 1995. [0073] Maynard, J. and Georgiou, G. Antibody engineering, Annu Rev Biomed Eng 2: 339-76, 2000. 45 [0074] McBride and Summerfelt, Plant Mol. Biol. 14:269-276, 1990. [0075] Mcgilligan, KM, et al., (1987), "Alpha-1-Antitrypsin Concentration In Human Milk," Pediatr Res 22(3):268-27o. [0076] Mitra A. and Zhang Z., Plant Physiol, 106:977-981, 1994. [0077] McGilligan, K.M. et a/., "Alpha-1-antitrypsin concentration in human milk," Pediatr. Res.
Load more

Recommended publications
  • University Microfilms International 300 N
    INFORMATION TO USERS This was produced from a copy of a document sent to us for microfilming. While the most advanced technological means to photograph and reproduce this document have been used, the quality is heavily dependent upon the quality of the material submitted. The following explanation of techniques is provided to help you understand markings or notations which may appear on this reproduction. 1. The sign or "target” for pages apparently lacking from the document photographed is "Missing Page(s)”. If it was possible to obtain the missing page(s) or section, they are spliced into the film along with adjacent pages. This may have necessitated cutting through an image and duplicating adjacent pages to assure you of complete continuity. 2. When an image on the film is obliterated with a round black mark it is an indication that the film inspector noticed either blurred copy because of movement during exposure, or duplicate copy. Unless we meant to delete copyrighted materials that should not have been filmed, you will find a good image of the page in the adjacent frame. If copyrighted materials were deleted you will find a target note listing the pages in the adjacent frame. 3. When a map, drawing or chart, etc., is part of the material being photo­ graphed the photographer has followed a definite method in “sectioning” the material. It is customary to begin filming at the upper left hand corner of a large sheet and to continue from left to right in equal sections with small overlaps. If necessary, sectioning is continued again—beginning below the first row and continuing on until complete.
    [Show full text]
  • Human Plasma and Recombinant Hemopexins: Heme Binding Revisited
    International Journal of Molecular Sciences Article Human Plasma and Recombinant Hemopexins: Heme Binding Revisited Elena Karnaukhova 1,*, Catherine Owczarek 2, Peter Schmidt 2, Dominik J. Schaer 3 and Paul W. Buehler 4,5,* 1 Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993, USA 2 CSL Limited, Bio21 Institute, Parkville, Victoria 3010, Australia; [email protected] (C.O.); [email protected] (P.S.) 3 Division of Internal Medicine, University Hospital of Zurich, 8091 Zurich, Switzerland; [email protected] 4 Department of Pathology, The University of Maryland School of Medicine, Baltimore, MD 21201, USA 5 The Center for Blood Oxygen Transport and Hemostasis, Department of Pediatrics, The University of Maryland School of Medicine, Baltimore, MD 21201, USA * Correspondence: [email protected] (E.K.); [email protected] (P.W.B.) Abstract: Plasma hemopexin (HPX) is the key antioxidant protein of the endogenous clearance pathway that limits the deleterious effects of heme released from hemoglobin and myoglobin (the term “heme” is used in this article to denote both the ferrous and ferric forms). During intra-vascular hemolysis, heme partitioning to protein and lipid increases as the plasma concentration of HPX declines. Therefore, the development of HPX as a replacement therapy during high heme stress could be a relevant intervention for hemolytic disorders. A logical approach to enhance HPX yield involves recombinant production strategies from human cell lines. The present study focuses on a biophysical assessment of heme binding to recombinant human HPX (rhHPX) produced in the Expi293FTM (HEK293) cell system.
    [Show full text]
  • An Interactomics Overview of the Human and Bovine Milk Proteome Over Lactation Lina Zhang1, Aalt D
    Zhang et al. Proteome Science (2017) 15:1 DOI 10.1186/s12953-016-0110-0 RESEARCH Open Access An interactomics overview of the human and bovine milk proteome over lactation Lina Zhang1, Aalt D. J. van Dijk2,3,4 and Kasper Hettinga1* Abstract Background: Milk is the most important food for growth and development of the neonate, because of its nutrient composition and presence of many bioactive proteins. Differences between human and bovine milk in low abundant proteins have not been extensively studied. To better understand the differences between human and bovine milk, the qualitative and quantitative differences in the milk proteome as well as their changes over lactation were compared using both label-free and labelled proteomics techniques. These datasets were analysed and compared, to better understand the role of milk proteins in development of the newborn. Methods: Human and bovine milk samples were prepared by using filter-aided sample preparation (FASP) combined with dimethyl labelling and analysed by nano LC LTQ-Orbitrap XL mass spectrometry. Results: The human and bovine milk proteome show similarities with regard to the distribution over biological functions, especially the dominant presence of enzymes, transport and immune-related proteins. At a quantitative level, the human and bovine milk proteome differed not only between species but also over lactation within species. Dominant enzymes that differed between species were those assisting in nutrient digestion, with bile salt- activated lipase being abundant in human milk and pancreatic ribonuclease being abundant in bovine milk. As lactation advances, immune-related proteins decreased slower in human milk compared to bovine milk.
    [Show full text]
  • Mrna Vaccine Era—Mechanisms, Drug Platform and Clinical Prospection
    International Journal of Molecular Sciences Review mRNA Vaccine Era—Mechanisms, Drug Platform and Clinical Prospection 1, 1, 2 1,3, Shuqin Xu y, Kunpeng Yang y, Rose Li and Lu Zhang * 1 State Key Laboratory of Genetic Engineering, Institute of Genetics, School of Life Science, Fudan University, Shanghai 200438, China; [email protected] (S.X.); [email protected] (K.Y.) 2 M.B.B.S., School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China; [email protected] 3 Shanghai Engineering Research Center of Industrial Microorganisms, Shanghai 200438, China * Correspondence: [email protected]; Tel.: +86-13524278762 These authors contributed equally to this work. y Received: 30 July 2020; Accepted: 30 August 2020; Published: 9 September 2020 Abstract: Messenger ribonucleic acid (mRNA)-based drugs, notably mRNA vaccines, have been widely proven as a promising treatment strategy in immune therapeutics. The extraordinary advantages associated with mRNA vaccines, including their high efficacy, a relatively low severity of side effects, and low attainment costs, have enabled them to become prevalent in pre-clinical and clinical trials against various infectious diseases and cancers. Recent technological advancements have alleviated some issues that hinder mRNA vaccine development, such as low efficiency that exist in both gene translation and in vivo deliveries. mRNA immunogenicity can also be greatly adjusted as a result of upgraded technologies. In this review, we have summarized details regarding the optimization of mRNA vaccines, and the underlying biological mechanisms of this form of vaccines. Applications of mRNA vaccines in some infectious diseases and cancers are introduced. It also includes our prospections for mRNA vaccine applications in diseases caused by bacterial pathogens, such as tuberculosis.
    [Show full text]
  • Nano-Lactoferrin in Diagnostic, Imaging and Targeted Delivery for Cancer and Infectious Diseases Jagat R
    cer Scien an ce C & f o T Kanwar et al., J Cancer Sci Ther 2012, 4.3 l h a e n r a Journal of 1000107 r p u DOI: 10.4172/1948-5956. y o J ISSN: 1948-5956 Cancer Science & Therapy Review Article Open Access Nano-Lactoferrin in Diagnostic, Imaging and Targeted Delivery for Cancer and Infectious Diseases Jagat R. Kanwar1*, Rasika M. Samarasinghe1, Rakesh Sehgal2 and Rupinder K. Kanwar1 1Nanomedicine-Laboratory of Immunology and Molecular Biomedical Research (LIMBR), Centre for Biotechnology and Interdisciplinary Biosciences (BioDeakin), Institute for Technology & Research Innovation (ITRI), Deakin University, Geelong, Technology Precinct (GTP), Pigdons Road, Waurn Ponds, Geelong, Victoria 3217, Australia 2Professor, Department of Parasitology, Postgraduate Institute of Medical Education & Research, Chandigarh, India-160012 Abstract Lactoferrin (Lf) is a natural occurring iron binding protein present in many mammalian excretions and involved in various physiological processes. Lf is used in the transport of iron along with other molecules and ions from the digestive system. However its the modulatory functions exhibited by Lf in connection to immune response, disease regression and diagnosis that has made this protein an attractive therapeutic against chronic diseases. Further, the exciting potentials of employing nanotechnology in advancing drug delivery systems, active disease targeting and prognosis have also shown some encouraging outcomes. This review focuses on the role of Lf in diagnosing infection, cancer, neurological and inflammatory diseases and the recent nanotechnology based strategies. Keywords: Lactoferrin; Nanodelivery; Cancer; Inflammation; fluids, mucosal secretions, pancreatic fluids and in neutrophils cells [8]. Infection; Oral administration Structurally, Lf weighs approximately 80kDa and the polypeptide folds into two globular lobes.
    [Show full text]
  • RHAMM, CD44 EXPRESSION and ERK ACTIVATION ARE LINKED in MALIGNANT HUMAN BREAST CANCER CELLS and ARE ASSOCIATED Wlth CELL Motlllty
    RHAMM, CD44 EXPRESSION AND ERK ACTIVATION ARE LINKED IN MALIGNANT HUMAN BREAST CANCER CELLS AND ARE ASSOCIATED WlTH CELL MOTlLlTY Frouz Frozan Paiwand A thesis submitted in conformity with the requirements for the degree of Master of Science Graduate Department of Laboratory Medicine and Pathobiology University of Toronto O Copyright by Frouz Frozan Paiwand 1999 National Library Bibliothèque nationale 1*1 of Canada du Canada Acquisitions and Acquisitions et Bibliographie Sewîes senrices bibliographiques 395 Wellington Street 395. rua Ws(lingt0ri OaawaON K1AW OFtswaON K1AONI canada CaMde The author has granted a non- L'auteur a accordé une licence non exclusive licence allowing the exclusive permettant à la National Library of Canada to Bibliothèque nationale du Canada de reproduce, loan, distribute or sell reproduire, prêter, distribuer ou copies of this thesis in microform, vendre des copies de cette thèse sous paper or electronic formats. la forme de rnicrofiche/nlm, de reproduction sur papier ou sur format électronique. The author retains owaership of the L'auteur conserve la propriété du copyright in this thesis. Neither the droit d'auteur qui protège cette thèse. thesis nor substantial extracts fiom it Ni la thèse ni des extraits substantiels may be printed or otherwise de celle-ci ne doivent être imprimés reproduced without the author's ou autrement reproduits sans son permission. autorisation. I dedicate this Master's thesis to my rnother, who is the source of my inspiration, and to rny family for their never-ending love and support. RHAMM, CD44 Expression and ERK Activation are Linked in Human Breast Cancer Cells and are Associated with Cell Motility Frouz Frozan Paiwand Master of Science, 1999 Department of Laboratory Medicine and Pathobiology University of Toronto ABSTRACT We assessed CD44 RHAMM,erk, and ras expression in human breast cancer ce11 lines that Vary as xenografts in nude mice.
    [Show full text]
  • Regulation of Intracellular Heme Trafficking Revealed by Subcellular Reporters
    Regulation of intracellular heme trafficking revealed by subcellular reporters Xiaojing Yuana,b, Nicole Rietzschela,b, Hanna Kwonc, Ana Beatriz Walter Nunod, David A. Hannae,f, John D. Phillipsg, Emma L. Ravenh, Amit R. Reddie,f, and Iqbal Hamzaa,b,1 aDepartment of Animal & Avian Sciences, University of Maryland, College Park, MD 20742; bDepartment of Cell Biology & Molecular Genetics, University of Maryland, College Park, MD 20742; cDepartment of Molecular and Cell Biology, University of Leicester, Leicester LE1 9HN, United Kingdom; dInstituto de Bioquímica Médica, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-590, Brazil; eSchool of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, GA 30332; fParker H. Petit Institute of Bioengineering and Biosciences, Georgia Institute of Technology, Atlanta, GA 30332; gDivision of Hematology, University of Utah School of Medicine, Salt Lake City, UT 84132; and hDepartment of Chemistry, University of Leicester, Leicester LE1 7RH, United Kingdom Edited by Sabeeha S. Merchant, University of California, Los Angeles, CA, and approved July 11, 2016 (received for review June 20, 2016) Heme is an essential prosthetic group in proteins that reside in synthesized in the mitochondria or imported from the environ- virtually every subcellular compartment performing diverse bi- ment, heme has to be translocated across membrane barriers (22, ological functions. Irrespective of whether heme is synthesized in the 23). It has been suggested that the majority of extracellular heme mitochondria or imported from the environment, this hydrophobic is degraded through the heme oxygenase pathway to extract iron and potentially toxic metalloporphyrin has to be trafficked across from the porphyrin in mammalian cells (22, 24–28).
    [Show full text]
  • Systematic Mapping of BCL-2 Gene Dependencies in Cancer Reveals Molecular Determinants of BH3 Mimetic Sensitivity
    ARTICLE DOI: 10.1038/s41467-018-05815-z OPEN Systematic mapping of BCL-2 gene dependencies in cancer reveals molecular determinants of BH3 mimetic sensitivity Ryan S. Soderquist1, Lorin Crawford 2,3, Esther Liu1, Min Lu1, Anika Agarwal1, Grace R. Anderson1, Kevin H. Lin1, Peter S. Winter1, Merve Cakir1 & Kris C. Wood1 1234567890():,; While inhibitors of BCL-2 family proteins (BH3 mimetics) have shown promise as anti-cancer agents, the various dependencies or co-dependencies of diverse cancers on BCL-2 genes remain poorly understood. Here we develop a drug screening approach to define the sen- sitivity of cancer cells from ten tissue types to all possible combinations of selective BCL-2, BCL-XL, and MCL-1 inhibitors and discover that most cell lines depend on at least one combination for survival. We demonstrate that expression levels of BCL-2 genes predict single mimetic sensitivity, whereas EMT status predicts synergistic dependence on BCL- XL+MCL-1. Lastly, we use a CRISPR/Cas9 screen to discover that BFL-1 and BCL-w promote resistance to all tested combinations of BCL-2, BCL-XL, and MCL-1 inhibitors. Together, these results provide a roadmap for rationally targeting BCL-2 family dependencies in diverse human cancers and motivate the development of selective BFL-1 and BCL-w inhibitors to overcome intrinsic resistance to BH3 mimetics. 1 Department of Pharmacology and Cancer Biology, Duke University, Durham, NC 27710, USA. 2 Department of Statistics, Duke University, Durham, NC 27710, USA. 3Present address: Department of Biostatistics, Brown University School of Public Health, Providence, RI 02903, USA.
    [Show full text]
  • Quantitative Immunological Determination of 12 Plasma Proteins Excreted in Human Urine Collected Before and After Exercise
    Quantitative immunological determination of 12 plasma proteins excreted in human urine collected before and after exercise Jacques Poortmans, Roger W. Jeanloz J Clin Invest. 1968;47(2):386-393. https://doi.org/10.1172/JCI105735. Research Article Urine was collected from 6 healthy male adults at rest and from 20 male adults after a marathon race (25 miles). The concentrated urines were quantitatively analyzed, by single radial immunodiffusion, for their content in 12 different plasma proteins: tryptophan-rich prealbumin, albumin, α1-acid glycoprotein, α1-antitrypsin, ceruloplasmin, haptoglobin, Gc- globulin, transferrin, hemopexin, β2-glycoprotein I, γA-globulin, and γG-globulin. Albumin, γA-globulin, and γG-globulin represent the major part of the plasma proteins detected in normal urine excreted by humans at rest (12, 0.5, and 2.5 mg respectively, out of a total excretion of 17.5 mg of plasma proteins per 24 hr). The other plasma proteins were excreted at a lower rate (< 0.4 mg/24 hr). The relative content of tryptophan-rich prealbumin, α1-antitrypsin, Gc-globulin, transferrin, and γG-globulin was lower in normal urine than in normal serum, whereas that of α1-acid glycoprotein, β2-glycoprotein I, and γA-globulin was higher. The ratio of γG-globulin to γA-globulin was 4.9:1. When plotted on a logarithmic scale, no direct relationship between the molecular weight of a protein and the value of its renal clearance could be observed. Strenuous exercise increased (up to 50-fold) the excretion of plasma proteins which represent 82% of the total proteins found in urine, instead of 57% in urine collected from humans at rest.
    [Show full text]
  • Uncoupling of Myelin Assembly and Schwann Cell Differentiation by Transgenic Overexpression of Peripheral Myelin Protein 22
    The Journal of Neuroscience, June 1, 2000, 20(11):4120–4128 Uncoupling of Myelin Assembly and Schwann Cell Differentiation by Transgenic Overexpression of Peripheral Myelin Protein 22 Stephan Niemann,1 Michael W. Sereda,1 Ueli Suter,2 Ian R. Griffiths,3 and Klaus-Armin Nave1 1Zentrum fu¨ r Molekulare Biologie (ZMBH), University of Heidelberg, D-69120 Heidelberg, Germany, 2Institute of Cell Biology, Department of Biology, Swiss Federal Institute of Technology, Eidgeno¨ ssische Technische Hochschule- Hoenggerberg, CH-8093 Zu¨ rich, Switzerland, and 3Applied Neurobiology Group, Department of Veterinary Clinical Studies, University of Glasgow, Glasgow G61 1QH, United Kingdom We have generated previously transgenic rats that overexpress thermore, an aberrant coexpression of early and late Schwann peripheral myelin protein 22 (PMP22) in Schwann cells. In the cell markers was observed. PMP22 itself acquires complex nerves of these animals, Schwann cells have segregated with glycosylation, suggesting that trafficking of the myelin protein axons to the normal 1:1 ratio but remain arrested at the pro- through the endoplasmic reticulum is not significantly impaired. myelinating stage, apparently unable to elaborate myelin We suggest that PMP22, when overexpressed, accumulates in sheaths. We have examined gene expression of these dysmy- a late Golgi–cell membrane compartment and uncouples mye- elinating Schwann cells using semiquantitative reverse lin assembly from the underlying program of Schwann cell transcription-PCR and immunofluorescence analysis. Unex- differentiation. pectedly, Schwann cell differentiation appears to proceed nor- Key words: transgenic disease model; Charcot-Marie-Tooth mally at the molecular level when monitored by the expression neuropathy; myelin disease; axon-Schwann cell interaction; ab- of mRNAs encoding major structural proteins of myelin.
    [Show full text]
  • Milk Allergen by the Numbers
    Milk allergen component testing Bos d4 Milk Bos allergen d5 Bos by the d8 numbers Detect sensitizations to the complete milk protein to create personalized management plans for your patients. High levels of milk IgE may predict the likelihood of sensitivity, but may not be solely predictive of TC 2851 reactions to baked milk or α-lactalbumin allergy duration.1 • Susceptible to heat denaturation2 • HIGHER RISK of reaction to fresh milk1,3 • LOWER RISK of reaction Milk allergen to baked milk1,3,a • Patient likely to “outgrow” component testing milk allergy4 Measurement of specific IgE by blood test that provides objective assessment of sensitization to milk is the first step in discovering your patient’s allergy. Milk allergen component tests can help α-lactalbumin β-lactoglobulin Casein Test interpretations and next steps you determine the likelihood of reaction to baked goods, such as cookies or cheese pizza, as well as • Avoid fresh milk the likelihood of allergy persistence. + + - • Likely to tolerate baked milk products • Baked milk oral food challenge (OFC), Knowing which protein your patient is with a specialist may be appropriate sensitized to can help you develop a + - - • Likely to outgrow allergy management plan.3,5-9 - + - • Avoid all forms of milk +/- +/- + • Unlikely to become tolerant of milk over time • Avoid milk and baked milk products (yogurt, cookies, cakes), as well as products processed with milk (chocolate, sausage, potato chips) % of children with milk allergy 75 do not react to baked milk.3 Bos d4 Bos Bos d5 d8 TC 2852 TC 2853 β-lactoglobulin Casein Determine • Susceptible to heat • Resistant to heat which proteins denaturation2 denaturation3 your patient is • HIGHER RISK of reaction • HIGHER RISK of reaction to fresh milk1,3 to all forms of milk1,3,5 sensitized to.
    [Show full text]
  • Thrombocytopenia and Intracranial Venous Sinus Thrombosis After “COVID-19 Vaccine Astrazeneca” Exposure
    Journal of Clinical Medicine Article Thrombocytopenia and Intracranial Venous Sinus Thrombosis after “COVID-19 Vaccine AstraZeneca” Exposure Marc E. Wolf 1,2 , Beate Luz 3, Ludwig Niehaus 4 , Pervinder Bhogal 5, Hansjörg Bäzner 1,2 and Hans Henkes 6,7,* 1 Neurologische Klinik, Klinikum Stuttgart, D-70174 Stuttgart, Germany; [email protected] (M.E.W.); [email protected] (H.B.) 2 Department of Neurology, Universitätsmedizin Mannheim, University of Heidelberg, D-68167 Mannheim, Germany 3 Zentralinstitut für Transfusionsmedizin und Blutspendedienst, Klinikum Stuttgart, D-70174 Stuttgart, Germany; [email protected] 4 Neurologie, Rems-Murr-Klinikum Winnenden, D-71364 Winnenden, Germany; [email protected] 5 Department of Interventional Neuroradiology, The Royal London Hospital, Barts NHS Trust, London E1 1FR, UK; [email protected] 6 Neuroradiologische Klinik, Klinikum Stuttgart, D-70174 Stuttgart, Germany 7 Medical Faculty, University Duisburg-Essen, D-47057 Duisburg, Germany * Correspondence: [email protected]; Fax: +49-711-278-345-09 Abstract: Background: As of 8 April 2021, a total of 2.9 million people have died with or from the coronavirus infection causing COVID-19 (Corona Virus Disease 2019). On 29 January 2021, the European Medicines Agency (EMA) approved a COVID-19 vaccine developed by Oxford University Citation: Wolf, M.E.; Luz, B.; and AstraZeneca (AZD1222, ChAdOx1 nCoV-19, COVID-19 vaccine AstraZeneca, Vaxzevria, Cov- Niehaus, L.; Bhogal, P.; Bäzner, H.; ishield). While the vaccine prevents severe course of and death from COVID-19, the observation of Henkes, H. Thrombocytopenia and pulmonary, abdominal, and intracranial venous thromboembolic events has raised concerns. Objec- Intracranial Venous Sinus Thrombosis after “COVID-19 Vaccine tive: To describe the clinical manifestations and the concerning management of patients with cranial AstraZeneca” Exposure.
    [Show full text]